Manuel Merlos

List of Publications by Year
in descending order

121 papers	4,511 citations	109264 35 h-index	123376 61 g-index
123 all docs	123 docs citations	123 times ranked	5379 citing authors

#	Article	IF	Citations
1	Oleate Reverses Palmitate-induced Insulin Resistance and Inflammation in Skeletal Muscle Cells. Journal of Biological Chemistry, 2008, 283, 11107-11116.	1.6	285
2	Substituting Walnuts for Monounsaturated Fat Improves the Serum Lipid Profile of Hypercholesterolemic Men and Women. Annals of Internal Medicine, 2000, 132, 538.	2.0	243
3	New Azole Antifungals. 3. Synthesis and Antifungal Activity of 3-Substituted-4(3H)-quinazolinones1,2. Journal of Medicinal Chemistry, 1998, 41, 1869-1882.	2.9	203
4	Pharmacological properties of S1RA, a new sigmaâ€1 receptor antagonist that inhibits neuropathic pain and activityâ€induced spinal sensitization. British Journal of Pharmacology, 2012, 166, 2289-2306.	2.7	159
5	Synthesis and SAR of a New Series of COX-2-Selective Inhibitors:Â Pyrazolo[1,5-a]pyrimidines. Journal of Medicinal Chemistry, 2001, 44, 350-361.	2.9	158
6	Palmitate Induces Tumor Necrosis Factor-Î± Expression in C2C12 Skeletal Muscle Cells by a Mechanism Involving Protein Kinase C and Nuclear Factor-ÎºB Activation. Endocrinology, 2006, 147, 552-561.	1.4	155
7	Palmitate-Mediated Downregulation of Peroxisome Proliferator-Activated Receptor-Â Coactivator 1Â in Skeletal Muscle Cells Involves MEK1/2 and Nuclear Factor-ÂB Activation. Diabetes, 2006, 55, 2779-2787.	0.3	134
8	Synthesis and Structureâ^'Activity Relationship of a New Series of COX-2 Selective Inhibitors:â€‰ 1,5-Diarylimidazoles. Journal of Medicinal Chemistry, 2003, 46, 3463-3475.	2.9	128
9	Sigma 1 receptor: A new therapeutic target for pain. European Journal of Pharmacology, 2013, 716, 78-93.	1.7	117
10	Synthesis and Biological Evaluation of the 1-Arylpyrazole Class of Ïƒ₁ Receptor Antagonists: Identification of 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA,) Tj ETQq0 0 0 rgBT /Overlock 10	2.9	115
11	Activation of Peroxisome Proliferatorâ€“Activated Receptor Î²/Î´ Inhibits Lipopolysaccharide-Induced Cytokine Production in Adipocytes by Lowering Nuclear Factor-ÎºB Activity via Extracellular Signalâ€“Related Kinase 1/2. Diabetes, 2008, 57, 2149-2157.	0.3	108
12	Rupatadine: A new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. Drugs of Today, 2003, 39, 451.	2.4	77
13	Sigma-1 receptor antagonism as opioid adjuvant strategy: Enhancement of opioid antinociception without increasing adverse effects. European Journal of Pharmacology, 2013, 711, 63-72.	1.7	76
14	Modulation of PeripheralÎ¼-Opioid Analgesia byÏƒ₁Receptors. Journal of Pharmacology and Experimental Therapeutics, 2014, 348, 32-45.	1.3	74
15	The Ïƒ1 Receptor Engages the Redox-Regulated HINT1 Protein to Bring Opioid Analgesia Under NMDA Receptor Negative Control. Antioxidants and Redox Signaling, 2015, 22, 799-818.	2.5	71
16	PPARÎ²/Î´ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2011, 1811, 59-67.	1.2	66
17	Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction. Oncotarget, 2016, 7, 55840-55862.	0.8	66
18	The selective sigma-1 receptor antagonist E-52862 attenuates neuropathic pain of different aetiology in rats. Scientific Reports, 2016, 6, 24591.	1.6	61

#	Article	IF	Citations
19	Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A. Hepatology, 2009, 49, 106-115.	3.6	58
20	S1RA, a selective sigma-1 receptor antagonist, inhibits inflammatory pain in the carrageenan and complete Freundâ€™s adjuvant models in mice. Behavioural Pharmacology, 2014, 25, 226-235.	0.8	55
21	Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. Toxicology and Applied Pharmacology, 2011, 251, 32-40.	1.3	54
22	Investigational sigma-1 receptor antagonists for the treatment of pain. Expert Opinion on Investigational Drugs, 2015, 24, 883-896.	1.9	48
23	Sigma-1 Receptor and Pain. Handbook of Experimental Pharmacology, 2017, 244, 131-161.	0.9	46
24	Walnut-enriched diet increases the association of LDL from hypercholesterolemic men with human HepG2 cells. Journal of Lipid Research, 2001, 42, 2069-2076.	2.0	46
25	New Azole Antifungals. 2. Synthesis and Antifungal Activity of Heterocyclecarboxamide Derivatives of 3-Amino-2-aryl-1-azolyl-2-butanol1. Journal of Medicinal Chemistry, 1998, 41, 1855-1868.	2.9	43
26	Ïƒ1Receptors Are Involved in the Visceral Pain Induced by Intracolonic Administration of Capsaicin in Mice. Anesthesiology, 2013, 118, 691-700.	1.3	42
27	Intestinal anti-inflammatory activity of UR-12746, a novel 5-ASA conjugate, on acute and chronic experimental colitis in the rat. British Journal of Pharmacology, 2000, 130, 1949-1959.	2.7	41
28	Antinociception by Sigma-1 Receptor Antagonists. Advances in Pharmacology, 2016, 75, 179-215.	1.2	40
29	[(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine Derivatives as Dual Antagonists of PAF and Histamine. Journal of Medicinal Chemistry, 1994, 37, 2697-2703.	2.9	39
30	Down-regulation of acyl-CoA oxidase gene expression and increased NF-ÎºB activity in etomoxir-induced cardiac hypertrophy. Journal of Lipid Research, 2003, 44, 388-398.	2.0	39
31	Pharmacological Modulation of the Sigma 1 Receptor and the Treatment of Pain. Advances in Experimental Medicine and Biology, 2017, 964, 85-107.	0.8	39
32	Synthesis and structure-activity relationships of 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF antagonists. Journal of Medicinal Chemistry, 1993, 36, 2984-2997.	2.9	38
33	Relationship between plasma lipids and palmitoylâ€CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates. British Journal of Pharmacology, 1994, 112, 551-556.	2.7	38
34	Effects of PAFâ€antagonists in mouse ear oedema induced by several inflammatory agents. British Journal of Pharmacology, 1991, 104, 990-994.	2.7	37
35	Liquid fructose downregulates Sirt1 expression and activity and impairs the oxidation of fatty acids in rat and human liver cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 514-524.	1.2	37
36	Liquid fructose down-regulates liver insulin receptor substrate 2 and gluconeogenic enzymes by modifying nutrient sensing factors in rats. Journal of Nutritional Biochemistry, 2014, 25, 250-258.	1.9	36

#	Article	IF	Citations
37	Decreased susceptibility to copperâ€induced oxidation of ratâ€lipoproteins after fibrate treatment: influence of fatty acid composition. British Journal of Pharmacology, 1996, 117, 1155-1162.	2.7	34
38	Synthesis and Biological Evaluation of a New Series of Hexahydro-2H-pyrano[3,2-c]quinolines as Novel Selective Ïƒ₁ Receptor Ligands. Journal of Medicinal Chemistry, 2013, 56, 3656-3665.	2.9	34
39	Effects of the selective sigmaâ€1 receptor antagonist S1<scp>RA</scp> on formalinâ€induced pain behavior and neurotransmitter release in the spinal cord in rats. Journal of Neurochemistry, 2014, 129, 484-494.	2.1	34
40	Novel Azo Derivatives as Prodrugs of 5-Aminosalicylic Acid and Amino Derivatives with Potent Platelet Activating Factor Antagonist Activity. Journal of Medicinal Chemistry, 2001, 44, 3001-3013.	2.9	33
41	PGC-1ss Down-Regulation Is Associated With Reduced ERRÂ Activity and MCAD Expression in Skeletal Muscle of Senescence-Accelerated Mice. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2006, 61, 773-780.	1.7	32
42	Is the H4 receptor a new drug target for allergies and asthma. Frontiers in Bioscience - Elite, 2013, E5, 178-187.	0.9	32
43	The intestinal antiâ€inflammatory effect of dersalazine sodium is related to a downâ€regulation in ILâ€17 production in experimental models of rodent colitis. British Journal of Pharmacology, 2012, 165, 729-740.	2.7	31
44	Long-term protective effect of UR-12670 after warm renal ischemia in uninephrectomized rats. Kidney International, 1999, 56, 1798-1808.	2.6	30
45	A small molecule, orally active, Î± 4 Î² 1 /Î± 4 Î² 7 dual antagonist reduces leukocyte infiltration and airway hyper-responsiveness in an experimental model of allergic asthma in Brown Norway rats. British Journal of Pharmacology, 2006, 147, 661-670.	2.7	29
46	Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: A single-dose, randomized, open-label, two-way crossover study. Clinical Therapeutics, 2007, 29, 900-908.	1.1	29
47	Blockade of the Sigma-1 Receptor Relieves Cognitive and Emotional Impairments Associated to Chronic Osteoarthritis Pain. Frontiers in Pharmacology, 2019, 10, 468.	1.6	29
48	The Intestinal Anti-inflammatory Activity of UR-12746S on Reactivated Experimental Colitis Is Mediated Through Downregulation of Cytokine Production. Inflammatory Bowel Diseases, 2003, 9, 363-371.	0.9	28
49	Selective modification of rat hepatic microsomal fatty acid chain elongation and desaturation by fibrates: relationship with peroxisome proliferation. British Journal of Pharmacology, 1995, 114, 1351-1358.	2.7	27
50	New Water-Soluble Sulfonylphosphoramidic Acid Derivatives of the COX-2 Selective Inhibitor Cimicoxib. A Novel Approach to Sulfonamide Prodrugs. Journal of Medicinal Chemistry, 2004, 47, 5579-5582.	2.9	27
51	Disturbances in metabolic, transport and structural genes in experimental colonic inflammation in the rat: a longitudinal genomic analysis. BMC Genomics, 2008, 9, 490.	1.2	27
52	The Sigma-1 Receptor Antagonist, S1RA, Reduces Stroke Damage, Ameliorates Post-Stroke Neurological Deficits and Suppresses the Overexpression of MMP-9. Molecular Neurobiology, 2018, 55, 4940-4951.	1.9	27
53	Flavonoids as inhibitors of rat liver cytosolic glutathione S-transferase. Experientia, 1991, 47, 616-619.	1.2	26
54	Peroxisome Proliferator-Activated Receptor Â Down-Regulation Is Associated With Enhanced Ceramide Levels in Age-Associated Cardiac Hypertrophy. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2007, 62, 1326-1336.	1.7	26

#	Article	IF	Citations
55	Metabolic Alterations and Increased Liver mTOR Expression Precede the Development of Autoimmune Disease in a Murine Model of Lupus Erythematosus. PLoS ONE, 2012, 7, e51118.	1.1	26
56	Administration of a co-crystal of tramadol and celecoxib in a 1:1 molecular ratio produces synergistic antinociceptive effects in a postoperative pain model in rats. European Journal of Pharmacology, 2018, 833, 370-378.	1.7	26
57	Sigmaâ€1 receptor modulates neuroinflammation associated with mechanical hypersensitivity and opioid tolerance in a mouse model of osteoarthritis pain. British Journal of Pharmacology, 2019, 176, 3939-3955.	2.7	26
58	Co-crystal of tramadol-celecoxib: preclinical and clinical evaluation of a novel analgesic. Expert Opinion on Investigational Drugs, 2019, 28, 399-409.	1.9	26
59	Repeated Sigma-1 Receptor Antagonist MR309 Administration Modulates Central Neuropathic Pain Development After Spinal Cord Injury in Mice. Frontiers in Pharmacology, 2019, 10, 222.	1.6	25
60	Dual effect of a new compound, rupatadine, on edema induced by platelet-activating factor and histamine in dogs: Comparison with antihistamines and PAF antagonists. Drug Development Research, 1996, 39, 12-18.	1.4	24
61	A Complementary Scale of Biased Agonism for Agonists with Differing Maximal Responses. Scientific Reports, 2017, 7, 15389.	1.6	24
62	Atorvastatin prevents peroxisome proliferator-activated receptor Î³ coactivator-1 (PGC-1) downregulation in lipopolysaccharide-stimulated H9c2 cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1736, 120-127.	1.2	23
63	Discovery of EST73502, a Dual Î¼-Opioid Receptor Agonist and Ïƒ₁ Receptor Antagonist Clinical Candidate for the Treatment of Pain. Journal of Medicinal Chemistry, 2020, 63, 15508-15526.	2.9	23
64	Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study. Clinical Therapeutics, 2008, 30, 1639-1650.	1.1	22
65	The Role of Peroxisome Proliferator-Activated Receptor Î²/Î´ on the Inflammatory Basis of Metabolic Disease. PPAR Research, 2010, 2010, 1-11.	1.1	22
66	Design, Synthesis, and Structureâ^'Activity Relationship Studies of Novel 1-[(1-Acyl-4-piperidyl)methyl]-1H-2-methylimidazo[4,5-c]pyridine Derivatives as Potent, Orally Active Plateletâ^'Activating Factor Antagonists. Journal of Medicinal Chemistry, 1996, 39, 487-493.	2.9	21
67	Down-Regulation of Acyl-CoA Oxidase Gene Expression in Heart of Troglitazone-Treated Mice through a Mechanism Involving Chicken Ovalbumin Upstream Promoter Transcription Factor II. Molecular Pharmacology, 2003, 64, 764-772.	1.0	21
68	Blockade of sigma 1 receptors alleviates sensory signs of diabetic neuropathy in rats. European Journal of Pain, 2017, 21, 61-72.	1.4	21
69	Inhibitory effects of rupatadine on mast cell histamine release and skin wheal development induced byAscaris suum in hypersensitive dogs. Drug Development Research, 1998, 44, 49-55.	1.4	19
70	COLD ISCHEMIA IN THE ABSENCE OF ALLOREACTIVITY INDUCES CHRONIC TRANSPLANT NEPHROPATHY THROUGH A PROCESS MEDIATED BY THE PLATELET-ACTIVATING FACTOR1. Transplantation, 2000, 70, 1624-1631.	0.5	19
71	Evaluation of Responsive Gene Expression as a Sensitive and Specific Biomarker in Patients with Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, 221-229.	0.9	19
72	Effects of centrally acting analgesics on spinal segmental reflexes and windâ€up. European Journal of Pain, 2015, 19, 1012-1020.	1.4	19

#	Article	IF	Citations
73	UR-1505, a New Salicylate, Blocks T Cell Activation through Nuclear Factor of Activated T Cells. Molecular Pharmacology, 2007, 72, 269-279.	1.0	18
74	Ligands Exert Biased Activity to Regulate Sigma 1 Receptor Interactions With Cationic TRPA1, TRPV1, and TRPM8 Channels. Frontiers in Pharmacology, 2019, 10, 634.	1.6	18
75	In vitro study of caffeic acid â€" bovine serum albumin interaction. European Journal of Drug Metabolism and Pharmacokinetics, 1988, 13, 11-14.	0.6	17
76	Effects of URâ€12633, a new antagonist of plateletâ€activating factor, in rodent models of endotoxic shock. British Journal of Pharmacology, 1996, 118, 1223-1231.	2.7	17
77	Atorvastatin inhibits GSK-3Î² phosphorylation by cardiac hypertrophic stimuli. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2008, 1781, 26-35.	1.2	17
78	Tissue factor pathway inhibitor 2 is induced by thrombin in human macrophages. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 1254-1260.	1.9	17
79	Evaluation of Formalin-Induced Pain Behavior and Glutamate Release in the Spinal Dorsal Horn Using In Vivo Microdialysis in Conscious Rats. Journal of Pharmacological Sciences, 2012, 120, 129-132.	1.1	16
80	Disubstituted tetrahydrofurans and dioxolanes as platelet activating factor (PAF) antagonists. Journal of Medicinal Chemistry, 1991, 34, 373-386.	2.9	15
81	The intestinal anti-inflammatory effects of the novel agent UR-1505 in the TNBS model of rat colitis are mediated by T-lymphocyte inhibition. Biochemical Pharmacology, 2007, 74, 1496-1506.	2.0	15
82	Comparative Study of the Effect of CV-6209, a Specific PAF-Antagonist, on Rat Paw Edema Caused by Different Phlogogen Agents. Pharmacology, 1990, 40, 211-217.	0.9	14
83	Differential effects of fibrates on the acyl composition of microsomal phospholipids in rats. British Journal of Pharmacology, 1995, 116, 2067-2075.	2.7	14
84	Topical anti-inflammatory properties of flutrimazole, a new imidazole antifungal agent. Inflammation Research, 1996, 45, 20-25.	1.6	14
85	Structure-activity relationships in a series of xanthine derivatives with antibronchoconstrictory and bronchodilatory activities. European Journal of Medicinal Chemistry, 1990, 25, 653-658.	2.6	13
86	Fibrates modify rat hepatic fatty acid chain elongation and desaturation in vitro. Biochemical Pharmacology, 1993, 46, 1791-1796.	2.0	13
87	Effect of 4-trifluoromethyl derivatives of salicylate on nuclear factor Îº B-dependent transcription in human astrocytoma cells. British Journal of Pharmacology, 2001, 132, 547-555.	2.7	13
88	Changes in saccharin preference behavior as a primary outcome to evaluate pain and analgesia in acetic acid-induced visceral pain in mice. Journal of Pain Research, 2015, 8, 663.	0.8	13
89	The Sigma 2 receptor promotes and the Sigma 1 receptor inhibits mu-opioid receptor-mediated antinociception. Molecular Brain, 2020, 13, 150.	1.3	13
90	Inhibition of rat liver microsomal fatty acid chain elongation by gemfibrozil in vitro. FEBS Letters, 1992, 300, 89-92.	1.3	12

#	Article	IF	Citations
91	Differential inhibition of long-chain acyl-CoA hydrolases by hypolipidemic drugs in vitro. Biochemical Pharmacology, 1992, 43, 639-644.	2.0	12
92	Different effects of fibrates on the microsomal fatty acid chain elongation and the acyl composition of phospholipids in guineaâ€pigs. British Journal of Pharmacology, 1995, 116, 3337-3343.	2.7	12
93	Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia. British Journal of Clinical Pharmacology, 1998, 45, 265-269.	1.1	12
94	Protective effect of URâ€12670 on chronic nephropathy induced by warm ischaemia in ageing uninephrectomized rats. Nephrology Dialysis Transplantation, 2001, 16, 735-741.	0.4	12
95	Antihistaminic effects of rupatadine and PKPD modelling. European Journal of Drug Metabolism and Pharmacokinetics, 2008, 33, 107-116.	0.6	12
96	Long-lasting reflexive and nonreflexive pain responses in two mouse models of fibromyalgia-like condition. Scientific Reports, 2022, 12, .	1.6	12
97	(Pyridylcyanomethyl)piperazines as orally active PAF antagonists. Journal of Medicinal Chemistry, 1992, 35, 4118-4134.	2.9	10
98	Pharmacological sensitivity of reflexive and nonreflexive outcomes as a correlate of the sensory and affective responses to visceral pain in mice. Scientific Reports, 2017, 7, 13428.	1.6	10
99	A New Model of Sensorial Neuron-Like Cells for HTS of Novel Analgesics for Neuropathic Pain. SLAS Discovery, 2019, 24, 158-168.	1.4	10
100	Urinary bladder sigma-1 receptors: A new target for cystitis treatment. Pharmacological Research, 2020, 155, 104724.	3.1	10
101	Cytosolic lipogenic enzymes: Effect of fibric acid derivatives in vitro. Life Sciences, 1993, 52, 213-222.	2.0	9
102	Influence of Lipid Profile and Fatty Acid Composition on the Oxidation Behavior of Rat and Guinea Pig Low Density Lipoprotein. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 1998, 119, 311-316.	0.7	9
103	UR-1505, a salicylate able to selectively block T-cell activation, shows intestinal anti-inflammatory activity in the chronic phase of the DSS model of rat colitis. Inflammatory Bowel Diseases, 2008, 14, 888-897.	0.9	9
104	In vitro effect of clofibric acid derivatives on rat hepatic microsomal electron transport chains. Biochemical Pharmacology, 1991, 42, 2057-2060.	2.0	8
105	Gemfibrozil modifies acyl composition of liver microsomal phospholipids from guinea-pigs without promoting peroxisomal proliferation. Biochemical Pharmacology, 1993, 46, 1515-1518.	2.0	8
106	Supraspinal and Peripheral, but Not Intrathecal, Ïƒ1R Blockade by S1RA Enhances Morphine Antinociception. Frontiers in Pharmacology, 2019, 10, 422.	1.6	8
107	4-Substituted 2-alkoxytetrahydrofurans as potent and long-lasting PAF antagonists. Journal of Medicinal Chemistry, 1992, 35, 676-683.	2.9	7
108	UR-60427, a novel H4 receptor-inverse agonist that shows good efficacy in a rat asthma model. Inflammation Research, 2010, 59, 199-200.	1.6	7

#	Article	IF	Citations
109	Outsideâ€in regulation of the readily releasable pool of synaptic vesicles by Î±2Îˆâ€1. FASEB Journal, 2020, 34, 1362-1377.	0.2	7
110	Inhibition of Cardiac Hypertrophy by Triflusal (4-Trifluoromethyl Derivative of Salicylate) and Its Active Metabolite. Molecular Pharmacology, 2006, 69, 1174-1181.	1.0	6
111	The New Salicylate Derivative UR-1505 Modulates the Th2/Humoral Response in a Dextran Sodium Sulphate Model of Colitis That Resembles Ulcerative Colitis. Journal of Pharmacological Sciences, 2009, 109, 315-318.	1.1	6
112	May a sigmaâ€1 antagonist improve neuropathic signs induced by cisplatin and vincristine in rats?. European Journal of Pain, 2018, 23, 603-620.	1.4	6
113	Characterization of [3H]apafant binding to PAF receptor on rabbit platelet membranes: A comparison of a Microplate Filtration System and a standard method. Journal of Pharmacological and Toxicological Methods, 1996, 36, 53-62.	0.3	5
114	Effect of endotoxin and platelet-activating factor on rat vascular permeability: role of vasoactive mediators. Journal of Lipid Mediators and Cell Signalling, 1997, 17, 31-45.	1.0	5
115	Comprehensive Preclinical Assessment of Sensory, Functional, Motivational-Affective, and Neurochemical Outcomes in Neuropathic Pain: The Case of the Sigma-1 Receptor. ACS Pharmacology and Translational Science, 2022, 5, 240-254.	2.5	5
116	Alternative Binding Assay of GP IIb/IIIa Antagonists With a Nonradioactive Labeling Method of Platelets. Thrombosis Research, 2001, 102, 247-253.	0.8	3
117	Development of a novel in vitro assay to screen for neuroprotective drugs against iatrogenic neurite shortening. PLoS ONE, 2021, 16, e0248139.	1.1	3
118	Identification of Novel Regulators of Zalcitabine-Induced Neuropathic Pain. ACS Chemical Neuroscience, 2021, 12, 2619-2628.	1.7	3
119	Design of potent linear PAF antagonists. Journal of Medicinal Chemistry, 1991, 34, 3328-3334.	2.9	2
120	Identification of Sodium Transients Through NaV1.5 Channels as Regulators of Differentiation in Immortalized Dorsal Root Ganglia Neurons. Frontiers in Cellular Neuroscience, 2022, 16, 816325.	1.8	1
121	Bronchodilator xanthine derivative with potent in vitro and in vivo activity after oral, parenteral or by inhalation administration. European Journal of Pharmacology, 1990, 183, 2125-2126.	1.7	0